Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age40+
SponsorIsfahan University of Medical Sciences
About this trial
The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema.
A blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo).
The evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.
Eligibility criteria
Qualifiers
None
Disqualifiers
Other retinal diseases except for DME and macular edema due to other causes including uveitis, epiretinal membrane, central retinal vein occlusion, and...
Existence of proliferative diabetic retinopathy and patients with a history of vitrectomy
Patients with glaucoma, vitreous hemorrhage, age-related macular degeneration (ARMD)
Media opacities that limit the interpretation of diagnostic tests
Trial design
Treatments tested in this trial
- bevacizumab with oral curcumin
- bevacizumab with oral placebo
Treatment groups
52 Participants
are divided into 2 treatment groupsLocations
1Mohsen Pourazizi8174673461, IsfahanIsfahan University of Medical Sciences, Iran
Sponsors and collaborators
Isfahan University of Medical Sciences
Lead sponsor
Source ClinicalTrials.gov